<SEC-DOCUMENT>0001973379-25-000186.txt : 20250612
<SEC-HEADER>0001973379-25-000186.hdr.sgml : 20250612
<ACCEPTANCE-DATETIME>20250612161804
ACCESSION NUMBER:		0001973379-25-000186
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250612
DATE AS OF CHANGE:		20250612

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		251042741

	BUSINESS ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020
		BUSINESS PHONE:		972 (3) 914-8213

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kalif Eliyahu Sharon
		CENTRAL INDEX KEY:			0001798443
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O TEVA, 5 BASEL STREET, P.O. BOX 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951033
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001798443</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0000818686</issuerCik>
      <issuerName>TEVA PHARMACEUTICAL INDUSTRIES LTD</issuerName>
      <secFileNumber>001-16174</secFileNumber>
      <issuerAddress>
        <com:street1>TEVA PHARMACEUTICAL INDUSTRIES LIMITED</com:street1>
        <com:street2>124 DVORA HANEVI'A ST.</com:street2>
        <com:city>TEL AVIV</com:city>
        <com:stateOrCountry>L3</com:stateOrCountry>
        <com:zipCode>6944020</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>972 (3) 914-8213</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Kalif Eliyahu Sharon</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
        <relationshipToIssuer>EVP CHIEF FINANCIAL OFFICER</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>CITIGROUP GLOBAL MARKETS</name>
        <address>
          <com:street1>390 GREENWICH ST</com:street1>
          <com:city>NEW YORK</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10013</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>55775</noOfUnitsSold>
      <aggregateMarketValue>952465.99</aggregateMarketValue>
      <noOfUnitsOutstanding>1146959855</noOfUnitsOutstanding>
      <approxSaleDate>06/12/2025</approxSaleDate>
      <securitiesExchangeName>NYSE</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <acquiredDate>03/06/2023</acquiredDate>
      <natureOfAcquisitionTransaction>SHARES FROM ROLLOVER</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>TEVA PHARMACEUTICAL INDUSTRIES LIMITED</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>33512</amountOfSecuritiesAcquired>
      <paymentDate>06/12/2025</paymentDate>
      <natureOfPayment>COMPENSATION</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <acquiredDate>03/04/2024</acquiredDate>
      <natureOfAcquisitionTransaction>SHARES FROM ROLLOVER</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>TEVA PHARMACEUTICAL INDUSTRIES LIMITED</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>22263</amountOfSecuritiesAcquired>
      <paymentDate>06/12/2025</paymentDate>
      <natureOfPayment>COMPENSATION</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>SHARES WERE SOLD PURSUANT TO COMPLY WITH RULE 10B51 C FROM A PLAN DATED DEC 3 24</remarks>
    <noticeSignature>
      <noticeDate>06/12/2025</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>12/03/2024</planAdoptionDate>
      </planAdoptionDates>
      <signature>CONFORMED SIGNATURE ON FILE</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
